Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Vanguard Growth Index Fund ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Vanguard Growth Index Fund ETF trades at $85.57. Which is the better fit depends on your goals.
| ACAD | VUG | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.06 | $90.29 |
52-Week Low | $20.06 | $70.00 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
VUG trades at $86.68, up 1.38% on the day, with a bullish technical signal from moving averages but bearish oscillators. The ETF recently executed a 1:6 stock split on April 21, 2026, and declared a $0.09 dividend payable June 30, 2026. Support sits near $85–$86, with resistance at $87–$88. Media coverage highlights its low 0.04% expense ratio and strong performance against active funds, though technology concentration at 56% of assets poses sector risk.
Outlook remains positive given cost efficiency and growth exposure, but investors face volatility from tech reliance and market sentiment shifts. The fund's large-cap focus offers stability, yet macroeconomic pressures could challenge returns. Risks include sector rotation and valuation sensitivity, balanced by long-term growth potential in U.S. equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
